



Pentokey Organy (India) Limited

Date: 12<sup>th</sup> August, 2023

BSE Limited  
P J Tower  
Dalal Street, Fort  
Mumbai, 400 001

Subject: Outcome of Board Meeting of Pentokey Organy (India) Limited held on 12th August, 2023.

Reference: BSE Scrip Code: 524210

Madam/ Sir,

This is to inform you that pursuant to Regulation 30 & Regulation 33 of Securities Exchange Board of India (Listing Obligation and Disclosure requirement) Regulation 2015 "Listing regulation" and other applicable provisions, the Board of Directors of the company at its meeting held today have approved the Unaudited Financial Results of the Company for the first quarter ended 30<sup>th</sup> June, 2023.

A Copy of the Unaudited Financial Results along with Limited Review Reports thereon are enclosed herewith for your information and record.

Further, pursuant to Regulation 47(1)(b) of the SEBI Listing Regulations, the Company would be publishing extract of Unaudited Financial Results for the first quarter ended 30<sup>th</sup> June, 2023.

The meeting of the Board of Directors of the Company commenced at 11.30 AM and concluded at 12.35 P.M.

This is for your information and records.

For PENTOKEY ORGANY (INDIA) LIMITED

  
Kostuv Kejriwal  
Director  
DIN: 00285687

**CIN: L24116MH1986PLC041681**

**Reg. Office: 509, Western Edge I, Western Express Highway, Borivali(East), Mumbai- 400 066**



Pentokey Organy (India) Limited

STATEMENT OF UNAUDITED FINANCIAL RESULTS FOR THE QUARTER ENDED 30TH JUNE, 2023

Particulars	Quarter Ended	Quarter Ended	Quarter Ended	Year Ended
	30.06.2023	31.03.2023	30.06.2022	31.03.2023
	Unaudited	Unaudited	Unaudited	Audited
I Revenue from Operations	229.54	60.78	36.45	436.55
II Other Income	11.20	10.69	6.63	235.60
III Total Income (I+II)	240.74	71.47	43.08	672.15
IV Expenses				
a) Purchase of Stock-in-trade / Cost of Materials Sold	261.10	64.87	34.65	341.38
b) Change in inventories of finished goods, work-in-progress and stock-in-t	(79.36)	(20.57)	-	(20.57)
c) Employee benefits expenses	4.17	2.46	4.53	13.78
d) Finance costs	0.60	2.85	-	2.85
e) Depreciation and amortisation expense	0.09	0.09	0.11	0.39
f) Others Expenses	11.28	2.03	5.81	16.77
Total Expenses	197.88	51.73	45.10	354.60
V Profit / (Loss) before exceptional items and tax (III-IV)	42.86	19.74	(2.02)	317.55
VI Exceptional items -	-	-	-	-
VII Profit / (Loss) after exceptional items and tax (V+VI)	42.86	19.74	(2.02)	317.55
VIII Tax expense				
Current Tax	-	-	-	-
IX Profit / (Loss) for the period from continuing operations (VII-VIII)	42.86	19.74	(2.02)	317.55
X Other Comprehensive Income				
(i) Items that will not be reclassified to profit or loss	0.25	(0.45)	(0.14)	0.15
(ii) Income tax relating to items that will not be reclassified to profit or loss		-	-	-
XI Total Comprehensive Income for the period ( IX+ X)	43.10	19.29	(2.16)	317.70
XII Earnings per equity share (for continuing operations)				
1) Basic	0.68	0.31	(0.03)	5.06
2) Diluted	0.68	0.31	(0.03)	5.06

NOTES:

- 1 The above results have been reviewed and recommended by the Audit Committee and subsequently approved by the Board of Directors in their meeting held on 12th August, 2023.
- 2 The above financial results have been reviewed by the statutory Auditors of the company and they have issued an unmodified Limited Review report of the same.
- 3 The above results pertain to "Pharma Segment" which is the only business segment of the Company.
- 4 The above results have been prepared in accordance with the Company's (Indian Accounting Standards), Rules, 2015 (Ind AS) prescribed under section 133 of the Companies Act, 2013 read with the rules thereunder and other recognised accounting practices and policies to the extent applicable.
- 5 The figures of the quarter ended 31 March, 2023 are the balancing figures between audited figures in respect of the full financial year and the published unaudited year to date figures up to third quarter of the financial year. Also, the figures upto the end of the third quarter were only reviewed and not subjected to audit.
- 6 Other Income in the Financial Results for the year ended 31st March, 2023 includes Rs.200 Lakhs towards recovery of Bad Debts provided for earlier.
- 7 The figures for the previous year and corresponding period have been regrouped, rearranged or recasted wherever necessary to conform to current period's presentation.

For Pentokey Organy (India) Limited

  
Kostuv Kejriwal  
Director  
DIN : 00285687

Place : Mumbai  
Date 12th August,2023

Reg. Office: 509, Western Edge I, Western Express Highway, Borivali (East), Mumbai -400066  
Tel no. +91-22-28545118/28545119 Website: www.pentokey.com  
CIN: L24116MH1986PLC041681





# VERMA MEHTA & ASSOCIATES

## Chartered Accountants

104, Creative Industries Premises, Sunder Nagar, Kalina, Sanatcruz (East) Mumbai 400098  
Tel : 2666 6359 Fax : 6693 5131 E-Mail - [vmaca92@gmail.com](mailto:vmaca92@gmail.com)

### INDEPENDENT AUDITOR'S REVIEW REPORT ON REVIEW OF INTERIM FINANCIAL RESULTS

To The Board of Directors

Pentokey Organy (India) Limited

1. We have reviewed the accompanying statement of unaudited standalone financial results of Pentokey Organy (India) Limited ("the Company"), for the Quarter ended June 30, 2023 ("the Statement"), together with the relevant notes thereon (the "Statement"). The Statement has been prepared by the Company pursuant to Regulation 33 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended. The Statement has been prepared in accordance with the recognition and measurement principles laid down in the Indian Accounting Standard 34 "Interim Financial Reporting" ("Ind AS 34"), prescribed under Section 133 of the Companies Act, 2013 read with relevant rules issued thereunder and other accounting principles generally accepted in India. Our responsibility is to issue a report on the Statement based on our review.

2. We conducted our review in accordance with the Standard on Review Engagements (SRE) 2410, "Review of Interim Financial Information Performed by the Independent Auditor of the Entity", issued by the Institute of Chartered Accountants of India. This Standard requires that we plan and perform the review to obtain moderate assurance as to whether the Statement is free of material misstatement.

3. A review is limited primarily to inquiries of company personnel and analytical procedures applied to financial data, and thus provide less assurance than an audit. We have not performed an audit and, accordingly, we do not express an audit opinion.





# VERMA MEHTA & ASSOCIATES

## Chartered Accountants

104, Creative Industries Premises, Sunder Nagar, Kalina, Sanatcruz (East) Mumbai 400098  
Tel : 2666 6359 Fax : 6693 5131 E- Mail - vmca92@gmail.com

4. Based on our review conducted as above, nothing has come to our attention that causes us to believe that the Statement has not been prepared in all material respects in accordance with Ind AS and other recognised accounting practices and policies, and has not disclosed the information required to be disclosed in terms of Regulation 33 of the Listing Regulations, 2015, as amended, including the manner in which it is to be disclosed, or that it contains any material misstatement.

For  
M/s Verma Mehta & Associates  
Chartered Accountants  
Firm's Registration No: 112118W

CA Rohit Rahalkar  
Partner  
M.N. 139232



Place: Mumbai  
Date: 12/08/2023

UDIN: 23139232B4RTFB9885

Branch Office: Pune | Aurangabad | Ahmedabad | Vadodara | Mohali